Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pentixapharm Holding AGXTER:PTP -0.79%19 Days Payable is 218.39 as of Jun. 2026, which is 50% below its 10-year median of 434.65. GuruFocus rates XTER:PTP with a GF Score™ of 19/100. The stock has 1 warning sign investors should review. Among 703 Biotechnology companies, Pentixapharm Holding AG ranks better than 53.34% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:PTP vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, Pentixapharm Holding AG's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pentixapharm Holding AG Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pentixapharm Holding AG's Days Payable distribution charts can be found below:
* The bar in red indicates where Pentixapharm Holding AG's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Pentixapharm Holding AG's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pentixapharm Holding AG (XTER:PTP) has a Days Payable of 218.39 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pentixapharm Holding AG and its competitors. This is 50% below median its historical median of 434.65. Over the past decade, Pentixapharm Holding AG's Days Payable has ranged from 125.97 to 563.75. According to the industry distribution chart, Pentixapharm Holding AG ranks #328 out of 703 companies in the Biotechnology industry, placing it in the top 46.7%.
Is Pentixapharm Holding AG's Days Payable too high?
Pentixapharm Holding AG's current Days Payable of 218.39 is 50% below median its 10-year median of 434.65. Over the past 10 years, this metric has ranged from a low of 125.97 to a high of 563.75. The Biotechnology industry median Days Payable is 112.39. Pentixapharm Holding AG's value of 218.39 is 94.3% above this industry median. Based on the distribution chart, Pentixapharm Holding AG ranks #328 out of 703 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Pentixapharm Holding AG has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Pentixapharm Holding AG's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pentixapharm Holding AG ranks #328 out of 703 companies for Days Payable. This puts Pentixapharm Holding AG in the upper half of its industry. The industry median Days Payable is 112.39. Pentixapharm Holding AG's value of 218.39 is 94.3% above this benchmark. Historically, Pentixapharm Holding AG's own Days Payable has ranged from 125.97 to 563.75 over the past decade. While the company's 10-year median is 434.65 vs. the industry median of 112.39, Pentixapharm Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.39, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pentixapharm Holding AG's current Days Payable of 218.39 is 94.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pentixapharm Holding AG and its competitors. For the Biotechnology industry, the median Days Payable is 112.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pentixapharm Holding AG's current Days Payable is 218.39, which is 50% below median its own 10-year median of 434.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pentixapharm Holding AG stock overvalued right now?
Pentixapharm Holding AG (XTER:PTP) has a current Days Payable of 218.39. The current Days Payable is 218.39, which is 50% below median its 10-year median of 434.65 and 94.3% above the Biotechnology industry median of 112.39. Pentixapharm Holding AG's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Pentixapharm Holding AG (XTER:PTP), the current Days Payable is 218.39 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic. Its Pipeline products include: Pentixa Ther, PT-002, PentixaFor, PT-001, PentixaFor, PT-001, PT-00X, GT-001, GT-002, GT-005, GT-008, and GT-00X.
19GF Score
Get the complete analysis for XTER:PTP
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:PTP has been successfully added to your 
